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Summary. The North American Multiple System Atrophy Study Group
involves investigators in 12 US medical centers funded by a grant from the
National Institutes of Health. The objectives are to examine the environmental
and genetic risk factors for MSA; elucidate pathogenic mechanisms underlying
the disorder; and refine evaluations used for assessment. During its first year, the
group enrolled 87 patients, implemented four cores, and initiated four scientific
projects. Most patients among the 87 had parkinsonian features, which fre-
quently began asymmetrically and remained asymmetrical; one-third responded
to levodopa and many developed levodopa complications; almost two-thirds of
the patients had cerebellar dysfunction, of these 90% had ataxia; urinary in-
continence occurred commonly, and sleep disorders affected most. The inves-
tigators studied the effects of oxidative and nitrative stress upon the formation
of alpha-synuclein inclusions; generated transgenic models of alpha-synuclein
accumulation that recapitulate several behavioral and neuropathological fea-
tures of MSA; and compared the severity of the autonomic features of MSA,
Parkinson’s disease and dementia with Lewy bodies.
Keywords: Multiple system atrophy, parkinsonism, cerebellar ataxia, autonomic
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Introduction
The North American Multiple System Atrophy (MSA) Study Group (NAMSA-
SG) consists of investigators in 12 participating medical centers in the United
States. Cliff Shults, M.D. organized the group and obtained funding through a
five-year program project grant from the National Institutes of Health, which
began on September 30, 2003. The overall specific aims of the program project
are to elucidate the risk factors for MSA, both environmental and genetic; study
pathogenic mechanisms contributing to the development of MSA; and evaluate
and refine clinical and laboratory assessments used to diagnoses and follow the
course of the illness. The program project consists of four scientific projects
supported by four cores. The principal investigators and co-investigators of the
projects include C.M. Tanner, M.D., Ph.D., Parkinson’s Institute and W. Kukull,
Ph.D., University of Washington (Project 1, Risk Factors for MSA); V.M.-Y.
Lee, Ph.D., University of Pennsylvania (Project 2, Mechanisms of Synuclein
Pathologies in MSA); C. Shults, M.D. and E. Masliah, M.D., University of
California San Diego (Project 3, Alpha-synuclein in Transgenic Models of
MSA); and P.A. Low, M.D. and P. Sandroni, M.D., Ph.D., Mayo Clinic (Project
4, Clinical and Laboratory Indices that Differentiate and Predict Outcome in
MSA and Parkinson’s Disease with Autonomic Failure). The principal investi-
gators and co-investigators of the cores include C. Shults, M.D., University of
California San Diego and Sid Gilman, M.D., University of Michigan (Core A,
Administrative and Clinical); R. Thomas, Ph.D. and S. May, Ph.D., University
of California San Diego (Core B, Data); J. Trojanowski, M.D., Ph.D., Univer-
sity of Pennsylvania (Core C, Neuropathology); and L. Ozelius, Ph.D., Albert
Einstein College of Medicine and Tatiana Foroud, Ph.D., Indiana University
(Core D, Genetics). In this summary of the NAMSA-SG, we will present briefly
a progress report of the first year of our activities.
Results and discussion
Participating sites
Table 1 lists the sites participating in the NAMSA-SG and the functions served
by these sites. Oversight of the program project comes from Dr. Shults at the
University of California San Diego, which contains the Administrative and Data
Cores as well as Project 3. Project 1 is performed at the Parkinson Institute. The
University of Pennsylvania houses the Neuropathology Core and Project 2;
Albert Einstein College of Medicine is home to the Genetics Core; and the
Mayo Clinic hosts Project 4. The remaining institutions serve as enrolling sites
for patients and control subjects who have no signs or symptoms of MSA.
When these institutions enroll subjects, they acquire a minimum data set, which
includes the principal features of the disorder (Tables 2–6). Enrollment occurs
at 11 of the 12 sites; the Albert Einstein College of Medicine does not enroll
subjects. Enrollment and data entry occurs via a secure web-based data entry
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system, which was developed within the first six months of the beginning of
grant funding.
MSA patients enrolled during
the first year
Over approximately 12 months, we have enrolled 87 patients with probable
MSA. These subjects include 56 male and 31 female subjects with a mean
age of 63 8.6 years (mean standard deviation). In this group, parkinsonian
and autonomic symptoms were the most common presenting features, followed
by cerebellar symptoms and combinations of symptoms (Table 2). Examination
revealed parkinsonian features in a high percentage of these patients, with
bradykinesia, postural instability of the parkinsonian type and rigidity affecting
a large majority of subjects (Table 3). Over one-third of these subjects had
resting tremor, two-thirds showed postural tremor, and approximately one-third
manifested persistent asymmetry. Also, more than half of the patients who
received levodopa treatment had a continuing beneficial response. Cerebellar
features also affected a majority of these subjects; unsteadiness and falls attri-
buted to cerebellar ataxia were found in most patients, and ataxia of gait, speech
and limbs was found in most of these patients (Table 4). Dysphagia was a
Table 1. Sites participating in the NAMSA-SG and functions served in the sites
– University of California San Diego
(Administrative and Data Cores, Project 3, Enrolling site)
– Parkinson Institute (Project 1, Enrolling site)
– University of Pennsylvania (Neuropathology Core, Project 2, Enrolling site)
– Mayo Clinic (Project 4, Enrolling site)
– Albert Einstein College of Medicine (Genetics Core)
– University of Maryland (Enrolling site)
– University of Rochester (Enrolling site)
– Boston University (Enrolling site)
– University Hospitals of Cleveland (Enrolling site)
– Baylor College of Medicine (Enrolling site)
– University of Michigan (Enrolling site)
– University of Virginia (Enrolling site)
Table 2. Type of symptom onset in the first MSA patients enrolled




Parkinsonianþ cerebellar 5=87 5.7
Parkinsonianþ autonomic 6=87 6.9
Cerebellarþ autonomic 0=87 0
Parkinsonianþ cerebellarþ autonomic 2=87 2.3
Ambiguous or incomplete information 14=87 16.1
Due to partially missing dates, the order of symptom onset could not be determined
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prominent symptom, affecting about two-thirds of patients. Autonomic dysfunc-
tion also affected most subjects, with urinary incontinence and incomplete blad-
der emptying reported in a large majority, and over one-third of subjects had a
history of postural syncope (Table 5). Also, fecal incontinence affected close to
one-third of patients. Among the males, erectile dysfunction was very frequent,
affecting 52 of the 56 men enrolled. Other prominent features include sleep
disorders in approximately two-thirds of patients, vivid dreams in about half,
and complaints of memory impairment in almost one-third of subjects (Table 6).
In summary, this data set reveals the following clinical trends: (1) parkin-
sonian features affect most subjects; (2) these features begin asymmetrically
and remain asymmetrical in a substantial number of cases; (3) approximately
Table 3. Parkinsonian features in the first MSA patients enrolled
Feature n=Total N Percent of patients
Bradykinesia 82=84 97.6
Rigidity 71=84 84.5
Postural instability 81=84 96.4
Resting tremor 33=84 39.3
Postural tremor 54=84 64.3
Unilateral onset 34=84 40.5
Persistent asymmetry 29=84 34.5
Levodopa response
Beneficial response 32=87 36.8
No response 26=87 29.9






Peak dose dyskinesias 6=22 27.3
Biphasic dyskinesias 1=22 4.6
Off-dystonia 7=22 31.8
Only for patients with parkinsonism, only for patients with motor complications
Table 4. Cerebellar features in the first MSA patients enrolled
Feature n=Total N Percent of patients
Cerebellar dysfunction
Gait ataxia 48=53 90.6
Ataxic dysarthria 42=53 79.2
Limb ataxia 46=53 86.8




Unsteadiness with falls 83=87 95.4
Only for patients with ataxia
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three quarters of the MSA patients had received levodopa, more than half
of these responded to levodopa, and many developed levodopa complications;
(4) ataxia appears in more than half of all patients and almost all patients
presenting with cerebellar dysfunction; (5) a majority of patients complain of
dysphagia; (6) urinary incontinence occurs frequently, much more commonly
than postural syncope; (7) about one-third of patients report fecal incontinence;
(8) sleep disorders affect about two-thirds of cases; and (9) memory impairment
and confusion are frequent complaints.
Research projects
Project 1 consists of an epidemiological study to investigate the determinants of
MSA using a case-control design. The project will investigate the hypotheses
that (1) specific occupational or avocational chemical exposure increases the
risk of MSA; (2) specific dietary factors directly affect the risk of MSA;
(3) exposure to the following can affect the risk of MSA: tobacco, caffeine,
alcohol, anti-inflammatory drugs and head trauma; and (4) familial aggregation
of MSA or associated neurodegenerative diseases will be found in the families
of persons with MSA. During the first year, this project has developed the
individual components of detailed lifetime history interviews and begun tele-
phone interviews with 79 subjects.
Project 2 will elucidate the effects of oxidative/nitrative stress upon the
formation of filamentous alpha-synuclein inclusions and assess the changes in
gene expression in alpha-synuclein aggregate-bearing oligodendrocytes in MSA.
The project has already demonstrated that oxidative and nitrative challenges
have differential effects on alpha-synuclein fibrillization and may cause alpha-
Table 5. Autonomic features in the first MSA patients enrolled
Feature n=Total N Percent of patients
Postural syncope 36=87 41.4
Urinary incontinence 77=87 88.5
Fecal incontinence 25=87 28.7
Incomplete bladder emptying 70=87 80.5
Male erectile dysfunction 52=56 92.9
Table 6. Other features in the first MSA patients enrolled
Feature n=Total N Percent of patients
Memory impairment 27=87 31.0
Confusion 15=87 17.2
Vivid dreams 40=87 46.0




Frontal release signs 15=87 17.2
Apraxia 7=87 8.0
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synuclein lesions through distinct mechanisms (Norris et al., 2003). The project
examined the pathological interactions of tau and alpha-synuclein in MSA and
related synucleinopathies, and detected tau and 14-3-3 proteins in subsets of
glial cytoplasmic inclusions (GCIs) (Giasson et al., 2003b). These findings
suggest that pathological interactions between alpha-synuclein and tau induce
tau fibrillization (Giasson et al., 2003a; Lee et al., 2004). In contrast to other
neurodegenerative disorders with tau inclusions, GCIs contain predominantly
hypophosphorylated species of tau. The project has generated monoclonal anti-
bodies to ubiquitin, synphilin and Parkin because these proteins have been im-
plicated in alpha-synuclein lesions (Murray et al., 2003; Pawlyk et al., 2003;
Sympathu et al., 2003). As many GCIs and other alpha-synuclein inclusions
were ubiquitin positive with the newly produced anti-ubiquitin monoclonal
antibodies, ubiquitination may be important in the pathogenesis of GCIs, but
ubiquitination of alpha-synuclein appears to be a downstream event in the
pathogenesis of GCIs (Sympathu et al., 2003). The Parkin monoclonal antibod-
ies produced in this project did not stain alpha-synuclein lesions even though
these antibodies are specific for Parkin, as shown by screening these antibodies
in Parkin knock-out mice and showing that the antibodies do not cross react
with other irrelevant proteins (Pawlyk et al., 2003). The synphilin monoclonal
antibodies stained a small subset of alpha-synuclein inclusions (Murray et al.,
2003). Thus, Parkin and synphilin may not be important in the pathogenesis of
alpha-synuclein lesions in MSA, while oxidative=nitrative mechanisms do con-
tribute to GCI formation, albeit by differentially modifying alpha-synuclein.
Project 3 will utilize transgenic models of alpha-synuclein accumulation
and aggregation to determine the behavioral, neurochemical and neuropatholog-
ical effects of alpha-synuclein accumulation and the effects of oxidative stress
and of nitration on the accumulation of alpha-synuclein. This project has already
created five transgenic mouse lines overexpresssing human alpha-synuclein
under the control of the murine myelin basic protein promoter, and these mice
recapitulate many of the behavioral and pathological features of MSA.
Project 4 will determine whether clinical and laboratory indices, especially
autonomic indices, will differentiate MSA, Parkinson’s disease, and Parkinson’s
disease with autonomic failure and will predict outcome. The project will also
undertake mechanistic studies to differentiate these disorders with investiga-
tions focused on autonomic regulation. Two studies have been completed, one
comparing autonomic deficits in dementia with Lewy bodies (DLB), MSA, and
Parkinson’s disease (PD), and the other focused on the quality of life in MSA.
The first study compared data from 20 DLB patients to 20 MSA and 20 PD
patients (Thaisetthawatkul et al., 2004). Orthostatic hypotension was found in
10=20 DLB, 17=20 MSA, and 1=20 PD patients (p¼ 0.023, 0.003). The results
of the Composite Autonomic Scoring Scale (CASS) were 5.2 2.0 for DLB,
8.1 1.3 for MSA, and 2.2 1.2 for PD (p<0.00001). The conclusions from
the study are that autonomic dysfunction occurs frequently in DLB and is
intermediate in severity between the autonomic disorders of MSA and PD.
The second study evaluated life satisfaction and the relationship of disease
parameters, physical function, and depressive symptoms to life satisfaction
in 98 MSA patients (Benrud-Larson et al., 2005). The study revealed low
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life satisfaction, with a mean of 38.8 on a 100-point visual analogue scale
(0¼ extremely dissatisfied, 100¼ extremely satisfied). Thirty-five percent of
patients reported moderate to severe depressive symptoms on the Beck Depres-
sion Inventory (BDI520). Data from the SF-36 Physical Component Summary
Scale were approximately 1.5 standard deviations below the mean of a nor-
mative sample of healthy adults the same age. Hierarchical regression anal-
ysis revealed that disease parameters (autonomic deficits, symptom severity,
and symptom duration) accounted for 22% of the variance in life satisfaction
(p<0.01). Physical function as measured by the SF-36 did not account for any
variance beyond the disease parameters; however, depressive symptoms ac-
counted for an additional 15% of the variance in life satisfaction (p<0.001).
These results suggest that among patients with MSA, depressive symptoms may be
an important determinant of life satisfaction in addition to disease-related factors
and should be assessed routinely. Treatment of comorbid depression may improve
quality of life in patients with MSA, despite the other debilitating deficits.
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